Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

ies from discontinued operations - 4,226

Long-term debt 575,000 575,000

Deferred income taxes 60,386 71,813

Other tax liabilities 2,425 -

Other long-term liabilities 4,614 4,052

Stockholders' equity 441,581 482,833

-------------------------------------------------------------------------

Total liabilities and stockholders' equity 1,151,188 1,205,874

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based on

historical fact, including without limitation statements containing the

words "believes," "may," "plans," "will," "estimate," "continue,"

"anticipates," "intends," "expects" and similar expressions, constitute

"forward-looking statements" within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995 and constitute "forward-looking

information" within the meaning of applicable Canadian securities laws.

All such statements are made pursuant to the "safe harbor" provisions of

applicable securities legislation. Forward-looking statements may

involve, but are not limited to, comments with respect to our strategies

or future actions, our targets, expectations for our financial condition

and the results of, or outlook for, our operations, research development

and product and drug development. Such forward-looking statements involve

known and unknown risks, uncertainties and other factors that may cause

the actual results, events or developments to be materially different'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
Breaking Biology News(10 mins):Kornberg Associates | Architects Completes UC Riverside Stem Cell Core Facility Project 2 Killer catfish? Venomous species surprisingly common, study finds 2New science estimates carbon storage potential of US lands 2PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 1PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 2PDF2Office for iWork New Utility to Convert PDF Files Directly to Native Keynote 26amp 3B Pages 26apos 3B08 26apos 3B09 Formats Ships 61205 3Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 1Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 2Oberthur Technologies 3A Major Security Certifications for the Identity Product Range 10700 3Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 1Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 2Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces 61197 3